Welcome to our dedicated page for Cosmos Holdings news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Holdings stock.
Cosmos Health Inc, also known as Cosmos Health, is a global healthcare group engaged in innovative R&D, pharmaceuticals & nutraceuticals manufacturing, and healthcare product distribution. The company owns proprietary brands like Sky Premium Life and Mediterranation, providing a wide range of products to healthcare providers. In recent news, the acquisition of Pelofarm's pharmacy distribution network in Greece shows Cosmos Health's strategic expansion and revenue growth.
Cosmos Health Inc. (NASDAQ:COSM) announced its fiscal year 2022 results, reporting revenues of $50.3 million, a decline from $56.2 million in FY2021 primarily due to foreign exchange variations. However, on a constant currency basis, revenue growth was noted at 0.71%. The company achieved positive Adjusted EBITDA of $0.5 million and significantly improved its financial position, ending 2022 with approximately $21 million in cash and long-term debt reduced by 76% to $5.1 million. Cosmos raised $56.5 million from equity offerings and warrant exercises. Amid market challenges, the CEO praised the company's strong performance and outlined plans for growth through acquisitions, including Cana Laboratories and ZipDoctor, enhancing the company’s vertical integration and entry into telehealth.
Cosmos Health (Nasdaq:COSM) announced its participation in The Economist Annual New York-Eastern Mediterranean Business Summit on July 10th, 2023, at the Lotte Palace, New York. CEO Greg Siokas will deliver a speech, partake in a Q&A, and engage in discussions about investment opportunities in the Eastern Mediterranean. The summit aims to explore the region's business potential with prominent speakers from the US, Israel, Greece, and Cyprus. Attendees include executives from various industries and institutional investors. This event highlights Cosmos Health's commitment to innovation, product development, and international expansion.
Cosmos Health Inc. (Nasdaq:COSM) has announced the completion of its acquisition of ZipDoctor, Inc. from American International Holdings Corp. This acquisition positions Cosmos Health in the growing telehealth market, projected to expand from $23.8 billion in 2021 to $309.9 billion by 2030, with a CAGR of 45.1%. ZipDoctor offers subscription-based telemedicine services, providing 24/7 access to healthcare professionals. Cosmos aims to enhance ZipDoctor's services and explore further innovations and partnerships to broaden its market reach.
Cosmos Health Inc. (Nasdaq:COSM) announced that its UK subsidiary, Decahedron Ltd., has been recognized as "Pharmaceutical Wholesaler of the Month" in the Mar/Apr 2023 issue of Healthcare Matters. Established in 2011, Decahedron Ltd. specializes in the import and export of pharmaceutical products across the EEA. The feature highlights Cosmos Health's Sky Premium Life brand, which offers over 75 nutraceutical products tailored for diverse dietary needs. CEO Greg Siokas noted the honor reflects the company's commitment to operational excellence and marketing innovations. Decahedron has expanded its product promotions globally, participating in key health exhibitions.
FAQ
What is the current stock price of Cosmos Holdings (COSM)?
What is the market cap of Cosmos Holdings (COSM)?
What is Cosmos Health Inc known for?
What proprietary brands does Cosmos Health Inc own?
What recent development has Cosmos Health Inc made?
Where does Cosmos Health Inc operate?